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Abstract:
A   case   control   study,   undertaken   in   the   department   of 
Obstetrics and Gynecology in a tertiary referral centre, was 
designed to administer standard dose of magnesium sulphate to 
50 randomly selected severely preeclamptic women in labor 
(Group 1). 48 women who formed the control group did not 
receive the drug (Group 2). The admission – delivery interval, 
rate of Cesarean section showed no statistically significant 
difference. Four patients developed convulsions in Group 1 in 
contrast to twelve patients in Group 2. Efficacy of magnesium 
sulphate at preventing eclampsia was calculated as 68%. Mild 
respiratory depression occurred in two cases and oliguria in 
eight cases in Group 1. Both the conditions improved on 
suspending further doses of magnesium sulphate. No patient 
had post partum haemorrhage in Group 1 although 4% patients 
had it in Group 2. Neonatal outcome was comparable in both 
the groups. Hence magnesium sulphate may be regarded as a 
fairly safe and effective prophylactic agent for eclampsia when 
used in severe preeclampsia in labor.
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Introduction:
Eclampsia is regarded as one of the most dangerous complica-
tions of preeclampsia and accounts for most of the maternal 
deaths in our country. Since the pathogenesis of eclampsia is 
not exactly known, the strategies for prevention are limited. 
Anticonvulsants are given to women with preeclampsia with 
the belief that they will prevent the onset of eclampsia and so 
improve the outcome for both mother and baby. Magnesium 
sulphate is a significantly better drug than either Diazepam or 
phenytoin for preventing recurrent seizures in eclamptic pa-
tients and is now considered as the drug of choice in treating 
eclampsia.(1) Magnesum sulpate has diverse cardiovascular 
and neurological effects. It alters calcium metabolism and 
crosses the placental barrier too. It has also to be kept in mind 
that even if eclampsia is prevented, it does not mean that other 
serious complications of preeclampsia can be avoided with this 
drug.(2) Hence the risk-benefit ratio has to be judged before 
routine administration of this drug in all women with pree-
clampsia. It is recommended that individual units determine 
their own protocols and monitor outcomes.(3)
Objective of the study: To determine the efficacy and safety of 
magnesium sulphate in preventing the development of eclamp-
sia in the severely preeclamptic patients in labor.
Materials and Methods:
The study was undertaken from March 2009 to February 2010 
in the department of Obstetrics and Gynecology of our institu-
tion which is a tertiary referral centre catering to four northern 
districts of West Bengal. The design of the study was an analyt-
ical case control type. Patients with severe preeclampsia, with 
blood pressure above 159/109mm of mercury were taken for 
the study. 50 patients were randomly selected to receive mag-
nesium sulphate. We used Pritchard’s protocol by which a load-
ing dose of 4g was given intravenously followed by intramus-
cular dose of 5g in each buttock. 5g of intramuscular dose was 
repeated every four hours upto 24 hours after delivery. 48 wo-
men who formed the control group, did not receive this drug. 
Hypertension was controlled with IV labetalol in either group. 
Both the study and control group were monitored for the dura-
tion of labor, mode of delivery, maternal complications like 
convulsions, respiratory depression, oliguria, hematuria, post-
partum hemorrhage, and fetal outcome was judged by the Ap-
gar score at five minutes of birth and duration of stay at neonat-
al care unit (NICU).
Statistical analysis:  All statistical analyses are done by the 
SPSS   software   version   17.   Comparison   between   maternal 
demographic   profiles   and   maternal   and   neonatal   outcome 
between the two groups is done by Chi-Square test. 
Results:
Table 1 shows that both the study and control groups were 
comparable as regards their age, gravida, gestational age on ad-
mission and duration of hypertension. Table 2 shows there 
doesn’t seem to be any significant prolongation of labor in the 
study group in comparison to the control group, since the ad-
mission delivery interval are similar. 50% (25 out of 50) of wo-
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women) had forceps application. In contrast, in Group 2, out of 
the 45.2% (22 women) who had vaginal delivery, 4.2% (2 wo-
men) needed forceps applications. (p<0.05, Chi-Square = 5.66). 
This difference seems to be significant statistically. The incid-
ence of Cesarean section was similar in both the groups – 50% 
in Group 1 and 54.2% in Group 2. Indication of operative deliv-
ery as labor dystocia, 22.85% in Group 1, which was more than 
Group   2,   at   7.14%   is   not   statistically   significant   (Chi-
Square=2.32,p>0.05). Fetal distress occurred equally in both 
the groups (Chi-Square=0.75, p>0.05). Four patients developed 
convulsions in Group 1 which is significantly lower than in 
Group2 that had an incidence of convulsion in 12 patients (Chi-
Square=5.79,p<0.05). Mild respiratory depression occurred in 
two cases and oliguria in 8 cases in the Group 1. The condition 
improved in all cases by suspending further doses of magnesi-
um sulphate. The incidence of Apgar score 7-10 between 
Group1, at 40% and Group 2 at 47.9% is comparable (Chi-
Square=o.62, p>0.05). Significantly more neonates were having 
an Apgar score 3-6 in Group 1 than in Group 2, 32% versus 
10.4% respectively (Chi-Square=6.78,p<0.01).
Table 1: Comparison of socio-demographic and antenatal 
variables between Group 1 and Group 2. 
  Group 1 Group 2 Total  P value
Age group
15-20 30 29 59 Chi-Square= 
0.25 p>0.05 20-25 17 15 32
>25 3 4 7
Gravida 
G1 38 40 78 Chi-Square= 
0.24 p>0.05 G2 11 8 19
G3 1 0 1
Gestational age on admission
28-36 
weeks
20 18 38
Chi-Square= 
1.08 p>0.05 37-40 
weeks
27 28 55
>40 weeks 1 0 1
Duration of hypertension
<2 weeks 2 3 5
Chi-Square= 
3.06 p>0.05
2-4 weeks 30 25 55
>4 weeks 2 0 2
Unknown  16 20 36
Table2: Comparison of the different obstetric outcome 
between Group 1 and Group 2. 
  Group1 
(n=50)
Group 
2(n=48) Total  P value
Admission delivery interval (hours)
1-5 15 17 32
Chi-Square= 
4.27 p>0.05
6-10 17 10 27
11-20 0 2 2
16-20 5 7 12
>20 13 12 25
Mode of delivery
Spontaneous vaginal 15 (30%)20 (41%) 35 Chi-Square= 
1.45 p>0.05
Forceps application 10 (20%)2 (4.2%) 12 Chi-Square= 
5.66 p<0.05
Cesarean section 25 (50%) 26 
(54.2%) 51 Chi-Square= 
0.17 p>0.05
Indication of operative delivery (Forceps and Cesarean section)
Indications  n= 35 n=28 Total 
  Uncontrolled hyper-
tension
15 
(42.8%) 14(50%) 29
Uncontrolled convul-
sion 2 (5.7%) 5 
(17.8%) 7 Chi-Square= 
2.32 p>0.05
Dystocia  8 
(22.8%) 2(7.14%) 10 Chi-Square= 
2.88 p>0.05
Fetal distress 10 
(28.5%)
7 (25%) 17 Chi-Square= 
0.75 p>0.05
Incidence of Apgar score <3 appears to be higher in Group 2 
(41.6%) than in Group1 (22.2%) but not significantly (Chi-
Square=0.08,p>0.05).
Efficacy of magnesium sulphate for preventing the incidence of 
convulsion [=(Incidence of convulsion among Group 2 - incid-
ence of convulsion in Group 1) × 100/Incidence of convulsion 
in Group 2)] was calculated to be 68%. [(25-8)×100/25 = 68]
Table 3: Maternal outcome in Group 1 and Group 2
Maternal complica-
tions Group1 Group 2 Total P value
Convulsion  4 (8%) 12 (25%) 16 Chi-
Square= 
5.79 
p<0.05 
(for con-
vulsion)
Oliguria  8 (16%) 5 (10.4%) 13
Hematuria  3 (6%) 5 (10.4%) 8
Respiratory depression 2 (4%) 0 (0%) 2
Blurred vision  2 (4%) 1 (2%) 3
PPH 0 (0%) 2 (4.1%) 2
No complications 31 26 57
Table 4: Neonatal outcome in Group 1 and Group 2 
  Group 1 
(n=50)
Group 2 
(n=48) Total  P value
Apgar score at five minutes of birth
7-10 20 (40%) 23 (47.9%) 43 Chi-Square= 
0.62 p>0.05
3-6 16 (32%) 5 (10.4%) 21 Chi-Square= 
6.78 p<0.01
<3 12 (24%) 20 (41.6%) 32 Chi-Square= 
1.77 p>0.05
Still birth 2 (4%) 0 (0%) 2  
Total  50 48 98  
Stay at NICU
<24 hours 4 5 9 Chi-Square= 
0.08 p>0.05 >24 hours 14 15 29
Total  18 20 38  
Discussion:
Eclampsia remains a complex and partially understood disease 
and its prophylaxis is the area of greatest controversy. Although 
magnesium sulphate is a proven anticonvulsant in eclampsia, its 
role in prophylaxis is less certain.
The American College of Obstetrician and Gynecologists re-
commends the use of magnesium sulphate in every woman with 
a diagnosis of preeclampsia during labor and the post partum 
period.(4) Hence it is the practice in different institutions to ad-
minister prophylactic magnesium sulphate to all women with 
preeclampsia during labor and for 24 hours postpartum.(2,5,6) 
But many have expressed concern at the potentially lethal side 
effects exerted by magnesium sulphate at the high doses that 
are to be attained to prevent convulsions.(2) The four large ran-
domized trials discussed by Sibai BM shows a lower rate of 
eclampsia in those assigned to magnesium sulphate (0.6% 
versus 2.0%). Thus the number of women needed to treat to 
prevent one case of eclampsia is 71.(7) Follow up data from 
Magpie Trial, where 9996 women were randomized in 33 coun-
tries to receive either magnesim sulphate, or placebo, shows a 
58% lower risk of eclampsia in the group made to receive mag-
nesium sulphate. The number of women with preeclampsia who 
needed to be treated to prevent one case of ecclampsia was 324 
in high GNI countries but 43 in low GNI countries. Restricting 
this prophylaxis for severe preeclampsia would lower the ex-
penditure considerably.(8,9) We had a much higher incidence 
of eclampsia in the severely preeclamptic mothers not receiving 
magnesium sulphate than the group receiving it (25% versus 
8%). Efficacy of magnesium sulphate to control convulsion is 
found to be 68%. Maternal respiratory  depression has been a 
serious concern.(7,10) Two women receiving the drug had res-
piratory depression but it was not significant when analyzed 
statistically. Although PPH has been reported to be associated 
with prophylactic magnesium sulphate use (11), we had no pa-
2tient with PPH although 4% in the control group. Magnesium 
sulphate did not affect the outcome of labor like admission de-
livery intervals and rate of Cesarean section. This conforms 
with some of the previous studies.(11,12) While one study re-
ports a high rate of Cesarean section (68.5%) done mostly due 
to fetal distress (38.6%) (13), we had a Cesarean delivery rate 
of 50% in the group receiving magnesium sulphate, mostly 
done for uncontrolled hypertension (42.8%) and fetal distress 
(28.5%). But the rate in the control group was similar with no 
statistically significant difference. Since magnesium sulphate 
crosses the placental barrier, there has been concern about its 
safety for the neonates. Some are of the opinion that the high 
cumulative doses of magnesium sulphate may be associated 
with infant mortality.(14) Even Sibai BM states that prophy-
lactic magnesium sulphate has no significant benefit in perinat-
al outcome.(7) The overall neonatal outcome was better in our 
study group as regards the Apgar scores and duration of stay at 
NICU with only two still births (4%). This is in accordance to 
some previous studies.(8,11)
The Magpie Trial showed no substantitive harmful effects on 
babies born to mothers on prophylactic magnesium sulphate in 
the short term. Follow up study done on the same subjects has 
further proved no death or neurosensory disability at the age of 
18 months for such babies.(15)
Conclusion:
Magnesium sulphate is a fairly safe and effective prophylactic 
agent for eclampsia when used during labor and 24 hours 
postpartum in women with severe preeclampsia. At the same 
time it should be accepted that even when given to women with 
the highest risk of eclampsia, it fails to prevent the onset of 
convulsion in all of them. Further studies are needed till we 
find the perfect antidote to this dreadful obstetric condition. 
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